生长激素缺乏的儿童和青少年血清基质金属蛋白酶2（MMP - 2）、基质金属蛋白酶9（MMP - 9）及金属蛋白酶组织抑制剂2（TIMP - 2）水平

[Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].

作者信息

Szczepańska-Kostro Jolanta, Kowalewski Marek, Urban Mirosława, Gardziejczyk Maria

机构信息

II Klinika Chorób Dzieci AM w Białymstoku.

出版信息

Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12(4):257-60.

PMID:17239302

Abstract

INTRODUCTION

Matrix metaloproteinases (MMPs) have been implicated in various pathological processes including inflammatory response, atherosclerosis and cardiovascular disease. Growth hormone deficiency (GHD) is associated with prematury atherosclerosis and cardiovascular disease. Circulating levels of matrix metaloproteinases and their tissue inhibitors (TIMPs) so far have not been assessed in children and adolescents with GHD.

MATERIAL AND METHODS

Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) were measured in 44 (11 girls and 33 boys) children and adolescents with newly diagnosed GHD [age (mean+/-SD) 12.5+/-2.7 years, height 1.3+/-0.1 m, body surface area (BSA) 1.1+/-0.2 m(2) and body mass index (BMI) 17.4+/-2.2 kg/m(2)] and in 32 (11 girls and 21 boys) healthy children and adolescents (age 12.4+/-2.9 years, height 1.6+/-0.2 m, BSA 1.4+/-0.3 m(2) and BMI 18.7+/-2.6 kg/m(2)). Human MMP-2, MMP-9 and TIMP-2 measurements were carried out with the use of ELISA kits.

RESULTS

Patients with GHD had significantly higher concentrations of MMP-2 (287.2+/-60.5 vs. 235.8+/-41.3 ng/ml, p<0.0001) and TIMP-2 (81.4+/-14.9 vs. 62.7+/-15.9 ng/ml, p<0.0001) levels than the control healthy group. There was no difference in MMP-9 levels (338.5+/-197.9 vs. 276.3+/-121.7 ng/ml, p=0.12) between patients with GHD and controls.

CONCLUSIONS

Children and adolescents with GHD have elevated serum concentrations of MMPs-2 and TIMP-2.

摘要

引言

基质金属蛋白酶（MMPs）参与了包括炎症反应、动脉粥样硬化和心血管疾病在内的多种病理过程。生长激素缺乏症（GHD）与过早发生的动脉粥样硬化和心血管疾病相关。目前尚未对患有GHD的儿童和青少年的循环基质金属蛋白酶及其组织抑制剂（TIMPs）水平进行评估。

材料与方法

对44名（11名女孩和33名男孩）新诊断为GHD的儿童和青少年[年龄（均值±标准差）12.5±2.7岁，身高1.3±0.1米，体表面积（BSA）1.1±0.2平方米，体重指数（BMI）17.4±2.2千克/平方米]以及32名（11名女孩和21名男孩）健康儿童和青少年（年龄12.4±2.9岁，身高1.6±0.2米，BSA 1.4±0.3平方米，BMI 18.7±2.6千克/平方米）的血清基质金属蛋白酶2（MMP-2）、基质金属蛋白酶9（MMP-9）和金属蛋白酶组织抑制剂2（TIMP-2）水平进行了测量。使用酶联免疫吸附测定（ELISA）试剂盒对人MMP-2、MMP-9和TIMP-2进行检测。

结果

GHD患者的MMP-2（287.2±60.5对235.8±41.3纳克/毫升，p<0.0‎001）和TIMP-2（81.4±14.9对62.7±15.9纳克/毫升，p<0.0‎001）水平显著高于健康对照组。GHD患者与对照组之间的MMP-9水平无差异（338.5±197.9对276.3±121.7纳克/毫升，p=0.12）。